Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
26 July 2024 | Story Valentino Ndaba | Photo Supplied
Gaza Panel Discussion 2024
A UFS panel discussion provides a platform for critical debate on the Israeli-Palestinian conflict.

The University of the Free State (UFS) recently facilitated an important panel discussion addressing the Israeli-Palestinian conflict, organised by the Free State Centre for Human Rights (FSCHR). The event brought together a diverse group of scholars to explore the ethical and political dimensions of universities’ engagement with pressing injustices such as the current crisis in Gaza.

Prof Danie Brand, Director of the FSCHR, opened the discussion by emphasising its significance. “UFS opens the space and takes this very important question forward,” he noted. The panel highlighted the necessity of academic institutions acting as platforms for critical debate, particularly on issues like the Gaza conflict.

Academic and intellectual dialogue

Prof Ulrike Kistner expressed gratitude to the UFS for initiating such dialogues, noting, "The UFS leads in fostering these important conversations." She emphasised the rarity of such discussions at other universities, highlighting UFS's unique role. A key point she raised was the importance of solidarity: “Solidarity entails acting with others because that is what they ask of us. It is a reason-driven rather than relationship-driven political action on others’ terms. Solidarity is a basic commitment to equity. Solidarity is a duty."

The conversation stressed the ethical imperative for universities to take a clear stance against violence and oppression. Prof Kelly Gillespie from the University of the Western Cape articulated this broader mission: "Universities must consider our engagement, not just as individuals, but as a collective guiding institutions towards creating a better world, rather than allowing ongoing inequality and crises to persist."

Prof Noor Nieftagodien, Head of the History Workshop at the University of the Witwatersrand, stated, "With our experience of apartheid, we in South Africa cannot remain silent. As institutions, we are looked to for moral, ethical, and political leadership, both locally and globally. We have a special responsibility to articulate a clear position on global crises, particularly the genocide in Gaza."

The role of universities in addressing global injustices

The discussion also addressed the destruction of educational institutions in Gaza and the killing of Palestinian teachers and academics, urging universities to engage with these injustices.

The panel discussion demonstrated the essential role of universities in addressing global injustice. By facilitating this event, the UFS contributes to the ongoing conversation on Gaza and lays the groundwork for future ethical action and solidarity within the academic community. The insights shared during the discussion resonate with the need for collective academic voices to influence broader societal and political landscapes, ensuring that critical issues are addressed with the urgency and depth they deserve.

View the panel discussion below:

 

News Archive

Nuclear Medicine on the forefront of cancer research
2017-07-10

Description: Nuclear Medicine on the forefront of cancer research Tags: Nuclear Medicine, cancer research, Dr Je’nine Horn-Lodewyk’s, tumour detection method, cancer, Department of Nuclear Medicine 

Dr Je’nine Horn-Lodewyk’s tumour detection method
could be the cost-effective breakthrough needed to decrease
the mortality rate in breast cancer patients.
Photo: Anja Aucamp

The field of Nuclear Medicine in South Africa and the rest of the world are expanding rapidly due to the development of hybrid cameras and new radiopharmaceuticals. These developments have a huge impact on the diagnosis and therapy of cancer.

The most advanced of these cameras, Positron emission tomography combined with normal CTs (PETCT), are not yet widely available in South Africa due to the cost of the cameras and the radiopharmaceuticals. A more cost-effective alternative can be of great benefit. To achieve this, the focus should be on developing new radiopharmaceuticals that can be used with the current cost-effective gamma cameras, according to University of the Free State researcher, Dr Je’nine Horn-Lodewyk from the Department of Nuclear Medicine.

Fluorodeoxyglucose (18F-FDG), a radiolabelled glucose analogue, is currently the radiopharmaceutical most commonly used in PET/CT imaging for mainly oncology indications. Although it is considered the gold standard for imaging in several malignancies, it does have certain disadvantages. An 18F-FDG PET/CT diagnostic imaging study can cost between R25 000 and R35 000 for a single patient in the private sector. The 18F-FDG is also more radioactive, which requires much stricter handling and shielding to avoid high radiation dosages to staff and patients.

Successful research potential innovative solution
In the search for the ideal radiopharmaceutical for tumour detection, the South African National Nuclear Energy Corporation (Necsa) developed a local synthesis process for ethylenedicysteine-deoxyglucose (EC-DG). EC-DG is also a glucose analogue similar to FDG. They succeeded in labelling the compound with Technetium-99-metastable-pertechnetate (99mTcO4-), the most common nuclear medicine isotope used for approximately 95% of nuclear medicine procedures, creating 99mTc-EC-DG.

In partnership with Dr Horn-Lodewyk, this compound was successfully used in various animal models and clinical scenarios, resulting in approval by the Medicine Control Council to use it in a human study. Research is also planned in order to investigate diagnostic accuracy in other cancers like lymphoma.  The end result of this research can produce a radiopharmaceutical that is cost effective, does not require the use of costly specialised equipment, has no significant side-effects, no special patient preparation, renders late imaging possible, and has decreased radiation risks.

Dr Horn-Lodewyk is grateful for the support of her mentor, Prof Anton Otto, as well as Dr Gert Engelbrecht, Head of the Department of Nuclear Medicine, Prof Jan Rijn Zeevaart from North-West University’s Preclinical Drug Development Platform and Necsa, and Judith Wagener from Necsa. This innovative research would also not have been possible without the financial assistance of Dr Glen Taylor and Eleanor van der Westhuizen in the Directorate of Research Development.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept